Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study

Herrera, Alex F.; McCord, Ronald; Kimes, Patrick K.; Jardin, Fabrice; Lenz, Georg; Trněný, Marek; Flowers, Christopher R.; Sehn, Laurie H.; Salles, Gilles; Sharman, Jeff P.; Tilly, Hervé; Friedberg, Jonathan W.; Herbaux, Charles; Matasar, Matthew J.; Haioun, Corinne; Tracy, Sam; Hirata, Jamie; Lee, Calvin; Jiang, Yanwen; Morschhauser, Franck

doi:10.1182/blood-2022-157559

Cited by 12 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…0.5, 0.98). With more than three years of median follow-up (39.7 months), the initial difference in PFS between the two arms was sustained (HR 0.76, 95% CI: 0.60-0.97) 28 .…”

Section: Pola-r-chp (Polarix)mentioning

confidence: 96%

Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma?

Ghione,

Salles

2024

haematol

View full text Add to dashboard Cite

Despite continuous improvements in the management and treatment of diffuse large B cell lymphoma (DLBCL), approximately 35% of the patients experience relapse or are refractory to frontline chemotherapy. For these patients, outcomes are far from satisfactory, and a real unmet need exists to both improve frontline treatment and create better options for relapsed/refractory disease. Polatuzumab vedotin is an anti-CD79b antibody conjugated to the monomethyl auristatin E (MMAE) microtubule inhibitor. The molecule has recently been under the spotlights for the promising results of the frontline combination with rituximab cyclophosphamide doxorubicin and prednisone (R-CHP) in the phase III POLARIX study, demonstrating improved progression-free survival over standard R-CHOP. A remarkable improvement in terms of complete response rate and overall survival with polatuzumab vedotin has also been achieved by combining polatuzumab with rituximab and bendamustine (pola-BR) over the standard BR for relapsed/refractory patients. Based on the results of these studies, health authorities in several countries granted approval for polatuzumab vedotin both for patients with previously untreated and for relapsed/refractory DLBCL. In this review, we summarize the data of major studies recently concluded with polatuzumab vedotin, and we provide an overview of the ongoing combination trials for frontline and relapsed/refractory DLBCL, outlining reported toxicities.

show abstract

“…0.5, 0.98). With more than three years of median follow-up (39.7 months), the initial difference in PFS between the two arms was sustained (HR 0.76, 95% CI: 0.60-0.97) 28 .…”

Section: Pola-r-chp (Polarix)mentioning

confidence: 96%

Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma?

Ghione,

Salles

2024

haematol

View full text Add to dashboard Cite

show abstract

“…Early and major molecular responses appear to be predictive of 24‐month event‐free survival (EFS) and OS in the frontline and salvage settings independent of the IPI 41 . Further, ctDNA appears to be effective in predicting progression‐free survival (PFS) and OS in response to polatuzumab, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola‐R‐CHP) (PFS HR 3.0, 95% CI 1.53–5.80; OS HR 2.7, 95% CI 1.07–7.02), axicabtagene ciloleucel (median PFS 3 months vs. NR, median OS 19 months vs. NR, p = .008), and ASCT (5‐year PFS and OS: 52% vs. 13% and 68% vs. 52% for undetectable and detectable ctDNA) 42–45 …”

Section: Ctdnamentioning

confidence: 99%

2024 Update: Advances in the risk stratification and management of large B‐cell lymphoma

Tavakkoli,

Barta

2023

American J Hematol

View full text Add to dashboard Cite

Diffuse large B‐cell lymphoma (DLBCL) is a heterogeneous disease with varying clinical outcomes. Our understanding of its molecular makeup continues to improve risk stratification, and artificial‐intelligence and ctDNA‐based analyses have the potential to enhance risk assessment and disease monitoring. R‐CHOP and Pola‐R‐CHP are used in the frontline setting; chimeric antigen receptor therapy (CART) is now the new standard‐of‐care for most with primary refractory disease; both CART and autologous stem cell transplantation are utilized in the relapsed and refractory setting. In this review, we summarize the classification and management of DLBCL with an emphasis on recent advances in the field.

show abstract

“…Herrera и соавт. [27] представили предварительные результаты анализа прогностической ценности циркулирующих опухолевых ДНК в исследовании POLARIX. У пациентов с наибольшим снижением их уровня до определенных значений после 1 цикла Pola-R-CHP наблюдалась более длительная выживаемость.…”

Section: Introductionunclassified

Polatuzumab vedotin in diffuse large B-cell lymphoma therapy: Literature review and experience of the Oncohematology Division of the Lapino Clinical Hospital

Ryabukhina,

Zeynalova,

Timofeeva

et al. 2024

jour

View full text Add to dashboard Cite

Study of molecular and genetic features of diffuse large B-cell lymphoma (DLBCL) suggests differential approach to treatment of this aggressive B-cell disorder characterized by short remission after each subsequent therapy line. Therefore, more effective regimens should be used at earlier stages. Identification of biological markers and their integration into prognostic scales can help to personalize therapy, especially in patients with high risk of quick progression and increase survival.Our own experience of using immunoconjugate polatuzumab vedotin in therapy of patients with DLBCL. The use of Pola-BR combination in a patient with refractory non-GCB DLBCL allowed to achieve full remission alongside satisfactory tolerability and absence of significant adverse events. An evaluation of the Pola-R-CHP regimen in treatment of a patient with newly diagnosed generalized GCB DLBCL is presented.

show abstract

Risk Profiling of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) By Measuring Circulating Tumor DNA (ctDNA): Results from the POLARIX Study

Cited by 12 publications

References 0 publications

Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma?

Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma?

2024 Update: Advances in the risk stratification and management of large B‐cell lymphoma

Polatuzumab vedotin in diffuse large B-cell lymphoma therapy: Literature review and experience of the Oncohematology Division of the Lapino Clinical Hospital

Contact Info

Product

Resources

About